Bone Biologics Corp
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
BBLG$0.33+3.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current Assets | ||
| Cash | $5,334,322 | $3,325,131 |
| Advances on research and development contract services | 208,972 | 258,059 |
| Prepaid insurance | 232,946 | 268,179 |
| Interest Receivable | 9,895 | - |
| Prepaid expenses | 10,000 | 10,000 |
| Total current assets | $5,796,135 | $3,861,369 |
| Total assets | $5,796,135 | $3,861,369 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities | ||
| Accounts payable and accrued expenses | $417,884 | $373,042 |
| Warrant liability | 703 | 4,670 |
| Total current liabilities | 418,587 | 377,712 |
| Total liabilities | 418,587 | 377,712 |
| Commitments and Contingencies | - | - |
| Stockholders’ Equity | ||
| Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at December 31, 2025 and 2024 | - | - |
| Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,795,260 and 492,417 shares issued and outstanding at December 31, 2025 and 2024, respectively(1) | 1,795 | 492 |
| Additional paid-in capital(1) | 93,506,122 | 88,504,543 |
| Accumulated deficit | (88,130,369) | (85,021,378) |
| Total stockholders’ equity | 5,377,548 | 3,483,657 |
| Total liabilities and stockholders’ equity | $5,796,135 | $3,861,369 |
| (1) | Adjusted to reflect the reverse stock split as described in Note 1. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.